Principles of the magnetic resonance imaging movie method for articulatory movement : a review

Magnetic resonance imaging (MRI) has become a critical tool for dental examination. MRI has many advantages over radiographic examination methods, including the lack of a requirement for patient exposure and the ability to capture high-contrast images of various tissue and organ types. However, MRI also has several limitations, including long examination times and the existence of metallic or motion artifacts. A cardiac imaging method using cine sequences was developed in the 1990s. This technique allows for analysis of heart movement and functional blood flow. Moreover, this method has been applied in dentistry. Recent research involving 3T MRI has led to the achievement of a temporal resolution of <10 ms, surpassing the frame rate of typical video recording. The current review introduces the history and principles of the cine sequence method and its application to the oral and maxillofacial regions

Influence of orthodontic appliance-derived artifacts on 3-T MRI movies

Abstract Background Magnetic resonance imaging (MRI) has been used to study configurations of speech organs in the resting state. However, MRI is sensitive to metals, and numerous types of metallic appliances, most of which have a large magnetic susceptibility, are used in orthodontic treatment and may cause severe artifacts on MRI. We have developed techniques for obtaining MRI movies of the oral region, to evaluate articulatory changes, especially movement of the tongue, palate, and teeth, pre- and post-orthodontic/orthognathic treatment. We evaluated the influence of artifacts caused by orthodontic appliances, including fixed retainers, metal brackets, and wires, on measurements in 3-T MRI movies. Methods Sixteen healthy young adults (nine males, seven females; average age, 27 years) with normal occlusion were recruited. Four types of customized maxillary and mandibular plates were prepared by incorporating one of the following into the plate: (a) nothing, (b) a fixed canine-to-canine retainer, (c) metal brackets for the anterior and molar teeth, or (d) clear brackets for the anterior teeth and metal brackets for molars. A 3-T MRI movie, in segmented cine mode, was generated for each plate condition while participants pronounced a vowel-consonant-vowel syllable (/asa/). The size of the artifact due to the metallic brackets was measured. The face size and orthodontically important anatomical structures, such as the velum, the hard palate, and the laryngeal ventricle, were also measured. Results A large artifact was observed over the entire oral region around orthodontic appliances, altering regional visibility. The velopharyngeal height was measured as significantly longer in the presence of metal brackets. The maximum artifact size due to a metallic bracket was > 8 cm. Our results show that even if it is possible to obtain the measurements of palate length, nasion to sella, and nasion to basion in individuals wearing metal brackets for molars, the measurements might be affected due to the presence of artifacts. Conclusions Orthodontic appliances, including metallic materials, sometimes produce significant measurement error in speech evaluation using MRI movies, which often become invisible or distorted by metallic orthodontic appliances. When the distorted image is measured, caution should be exercised, as the measurement may be affected. Based on the study, it is concluded that orthodontists should not necessarily remove all metallic appliances before MRI examination because the influence varies among the appliances and should also know that a significant measurement error in speech evaluation using MRI movie may occur by image distortion caused by metallic artifacts

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo